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bias when comparing costs and utilization between insulin lispro
and regular human insulin users. METHODS: A retrospective
analysis of medical and pharmacy claims was conducted among
users of insulin lispro or regular insulin during the identiﬁcation
period, March 1, 2000 to February 28, 2001. Propensity scores
(PS) were estimated using age, gender, comorbidities, use of oral
antidiabetic medications, prescription copayment, and baseline
period diabetes-related costs and utilization. Our binning analy-
ses classiﬁed all patients into ﬁve PS strata (quintiles). Overall
cost and utilization differences during the 12-month follow-up
period were then calculated using weights inversely proportional
to variances of within bin differences. In our matched analyses,
all subjects who could not be “paired” (1 :1 lispro to regular
insulin) with PS estimates agreeing within ±0.0001 were
excluded. RESULTS: Of 6436 subjects, 1972 (30.6%) received
insulin lispro and 4464 (69.4%) received regular insulin. At
baseline, lispro subjects were younger, had fewer comorbidities,
and were less likely to use oral antidiabetic medications than
regular insulin users. Within PS quintiles, there was no signiﬁ-
cant imbalance on baseline characteristics. When matching, only
969 well-matched subject pairs could be retained. Baseline char-
acteristics of these well-matched subjects were similar to those
of subjects in quintiles 3 and 4, indicating that matching had
tended to exclude subjects with extreme combinations of char-
acteristics (quintiles 1 and 5). CONCLUSIONS: Relative to
matching, the binning approach to adjustment for treatment
selection bias appears to provide an answer that is more easily
generalized to our full diabetic population. The binning
approach uses all available outcome data to estimate overall
treatment differences. Our analyses suggest that restrictions on
insulin lispro availability to save pharmacy costs may not be 
economically justiﬁable from a more comprehensive payer’s 
perspective.
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OBJECTIVES: The Cardiff Diabetes Cost Utility Model is a dis-
crete-event stochastic simulation model used to model macrovas-
cular and microvascular complications in diabetes. The model
was based on the Eastman DCCT model, and forecasts costs and
outcomes over a 20-year period using the UKPDS risk engines
for estimating cardiovascular events. This study used the Cardiff
model to estimate quality-adjusted life years (QALYs) and cost
of secondary care for patients with type-2 diabetes. METHODS:
Health utility was incorporated via the EQ5D utility instrument
using estimates derived from the Health Outcomes Data Repos-
itory (HODaR). This diabetes model accurately incorporates
health utility estimates for patients with individual and multiple
complication states. The model was run using baseline risk pro-
ﬁles used by Eastman and was compared with a 10% change in
individual and combined modiﬁable risk factors. We evaluated
the impact of these changes on the costs of secondary care events,
excluding drug costs. Costs were discounted at 6% and beneﬁts
at 1.5%. RESULTS: At baseline, the total discounted cost of 
hospital events was £5841 (£3305 for cardiovascular events 
and £2536 for microvascular events). Following a 10% change
in one of three modiﬁable risk factors, hospital event costs and
QALYs gained were driven by the total cholesterol to high-
density lipoprotein cholesterol ratio (TC:HDL-C) (-£392; 0.23
QALYs) and glycated hemoglobin (HbA1c) level (-£1236; 0.44
QALYs). TC:HDL-C had the greatest impact on cardiovascular
costs (-£423), and HbA1c had the greatest impact on microvas-
cular costs (-£890). These results were dependent on the age of
the population modeled: as age increased, HbA1c had less impact
on events and costs and TC:HDL-C had more impact. CON-
CLUSIONS: This study further demonstrates the importance of
TC:HDL-C and HbA1c on cost of macro- and microvascular
complications, respectively. This economic model is the ﬁrst to
reliably evaluate beneﬁt in terms of health utility.
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OBJECTIVES: To analyze the pharmacy and medical care 
costs of using different insulin-delivery methods, including pen-
injectors, disposable syringes, and traditional injection; and
examine the prevalence of hypoglycemic and hyperglycemic
events among patients on different delivery methods.
METHODS: Utilizing pharmacy and medical claims from a
managed care plan of over two million members, this study
selected continuously enrolled patients who received insulin or
insulin delivery products between July 1, 2000 and June 30,
2001, but did not have claims for these products in the six
months prior to the index date. The patients were divided into
three analysis groups based on initial insulin delivery method:
pen-injector, disposable syringe, or traditional injection. Phar-
macy and medical utilization, costs, and prevalence of hypo-
glycemic or hyperglycemic events in the 18 months following
index date were compared among the 3 groups. RESULTS:
Among the 3278 patients who received insulin products in the
12 months from July 1, 2000 to June 30, 2001, nearly 88% took
the traditional injection approach, only 12% adopted the deliv-
ery devices, including 146 patients (4.45%) who used pen injec-
tors and 250 patients (7.63%) who used disposable syringes.
Log-transformed linear regressions showed that pen-injector and
disposable users cost 58.5% and 50.3%, respectively, more than
patients using traditional injections in pharmacy expenditures,
but not in medical services expenditures, controlling for patient
demographics, comorbidities, community characteristics, and
type of health plan. Controlling for the same covariates, a logis-
tic regression indicated that the likelihood of having hypo-
glycemic or hyperglycemic events was similar between
traditional injection and the devices (p > 0.05). CONCLUSION:
This study did not ﬁnd signiﬁcant difference in medical costs and
insulin-related health events between patients who took insulin
via traditional injection and those adopted pen injectors or dis-
posable syringes, although traditional injections were less costly.
PDB17
RETIREE TYPE 2 DIABETES HEALTH CARE COSTS FOR A
SELF-INSURED TELECOMMUNICATIONS COMPANY
Erwin G1, Rajagopalan R2,Astuto J3,Wilson P4, Schaneman J5,
Kleinman N5
1Omnicare, Inc, King of Prussia, PA, USA; 2Takeda Pharmaceuticals
North America, Lincolnshire, IL, USA; 3Verizon Communications,
Alpharetta, GA, USA; 4Associates & Wilson, Rosemont, PA, USA;
5Options & Choices, Inc, Cheyenne, WY, USA
